Compare TGE & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | EDSA |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | France | Canada |
| Employees | 166 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 51.6M |
| IPO Year | N/A | 2018 |
| Metric | TGE | EDSA |
|---|---|---|
| Price | $0.91 | $5.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 35.5K | ★ 49.2K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $0.72 |
| 52 Week High | $4.40 | $20.32 |
| Indicator | TGE | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 45.73 |
| Support Level | $0.91 | $4.80 |
| Resistance Level | $1.22 | $5.82 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 44.14 | 75.18 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.